Recent BioBlast® Updates

Samsung Bioepis Enters Collaboration Agreement with Geo-Young For Biosimilar Distribution

Mar 22, 2024

On 22 March 2024, Korea Biomedical Review reported Geo-Young, South Korea's largest pharmaceutical distributor, signing a third-party logistics (3PL) contract with Samsung Bioepis for the distribution of biosimilar medicines within South Korea. This is the first...

New Indication Alert: BMS’s Abecma® (idecabtagene vicleucel) Receives EU Approval For Extended Indication

Mar 20, 2024

On 20 March, 2024, BMS announced that its CAR-T cell immunotherapy Abecma ® (idecabtagene vicleucel) was granted an extension of its therapeutic indication, now being approved for treatment of relapsed and refractory multiple myeloma (R/R MM) in patients undergoing...

Alvotech Reports Full Year Financial Results and Provides a Business Update

Mar 20, 2024

On 20 March 2024, Alvotech announced its full year financial results for 2023, highlighting increased product revenue and Alvotech’s acceptance of an offer from a group of investors for the sale of approximately 10 million ordinary shares in an Alvotech subsidiary for...

Novo Nordisk Announces USD 560 Million Investment in its Chinese Facility

Mar 20, 2024

On 20 March 2024, China Daily reported that Novo Nordisk has announced investing USD 560 million in its Chinese facility (in Tianjin which was first opened in 1994) as part of its expansion project to further increase manufacturing capability to support the...

Lonza Buys Vacaville (US) Biologics Site from Roche for $1.2 Billion to Increase Lonza’s Commercial Manufacturing Capabilities

Mar 20, 2024

On 20 March 2024, Lonza announced it has entered an agreement to acquire Genentech’s large-scale biologics manufacturing site in Vacaville, California (US) from Roche for US$1.2 Billion. The facility has a total capacity of around 330,000 liters which is reported to...

Dr Reddy’s Launches its First UK Biosimilar (bevacizumab) 5 Years After Indian Launch and 6 Years After First Bevacizumab UK Biosimilar Approval

Mar 19, 2024

On 19 March 2024, Dr. Reddy's announced the launch of its Versavo® (bevacizumab) in the UK. Versavo® is a biosimilar to Genentech’s Avastin®(bevacizumab) and is indicated for the treatment of several types of cancers, including metastatic colorectal cancer, advanced...

Fresenius & Formycon Settle with J&J in Europe and Canada over Ustekinumab Biosimilar

Mar 18, 2024

On 18 March 2024 Fresenius Kabi and Formycon announced they reached a settlement with Johnson & Johnson regarding the commercialisation of FYB202, biosimilar to J&J’s Stelara® (ustekinumab) in Europe and Canada. The announcements did not disclose the...

Bio-Thera Solutions Partners with SteinCares to Market Two Biosimilars in LATAM

Mar 18, 2024

On 18 March 2024, Bio-Thera Solutions announced that it is partnering with SteinCares to commercialise two unnamed biosimilars in LATAM. SteinCares will have exclusive right to distribute and market Bio-Thera’s two biosimilar pharmaceuticals in LATAM and Bio-Thera is...

Celltrion’s Sub-cutaneous Zymfentra™ (infliximab-dyyb) US Launched

Mar 18, 2024

On 17 March 2024, Celltrion USA launched ZYMFENTRA™ (infliximab-dyyb), the first subcutaneous formulation of infliximab approved by the U.S. FDA in 2023. Zymfentra is approved for maintenance therapy in adults with active ulcerative colitis or Crohn's disease...

November 2023 PBAC Public Summary Documents Feature Biopharma

Mar 15, 2024

On 15 March 2024, the Australian Department of Health and Aged Care published the public summary documents considered at the November 2023 PBAC meeting. Decisions included: Novo Nordisk’s Wegovy® (semaglutide) - PBAC refused PBS-listing for severe obesity; Organon’s...

CuraTeQ’s Omalizumab Biosimilar (BP11) Phase I Completion

Mar 15, 2024

On 15 March 2024, CuraTeQ Biologics (a subsidiary of Aurobindo) announced that it successfully completed phase I trials for omalizumab biosimilar (BP11), demonstrating pharmacokinetic and pharmacodynamic equivalence to Genentech’s/Novartis’ US and EU-sourced Xolair®....

Biocon Enters Long-Term Commercial Collaboration with Eris Lifesciences in India

Mar 14, 2024

On 14 March 2024, Biocon Biologics announced that it has entered a long-term commercial collaboration with Eris Lifesciences, including to increase access to its biosimilars in India. The deal, worth INR 12,420 million, involves a 10-year supply agreement with Eris...

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Subscribe here

PEARCE IP BLOG

Read our latest updates & insights

No Results Found

Recent BioBlast® Updates

Samsung Bioepis Enters Collaboration Agreement with Geo-Young For Biosimilar Distribution

New Indication Alert: BMS’s Abecma® (idecabtagene vicleucel) Receives EU Approval For Extended Indication

Alvotech Reports Full Year Financial Results and Provides a Business Update

Novo Nordisk Announces USD 560 Million Investment in its Chinese Facility

Lonza Buys Vacaville (US) Biologics Site from Roche for $1.2 Billion to Increase Lonza’s Commercial Manufacturing Capabilities

Dr Reddy’s Launches its First UK Biosimilar (bevacizumab) 5 Years After Indian Launch and 6 Years After First Bevacizumab UK Biosimilar Approval

Fresenius & Formycon Settle with J&J in Europe and Canada over Ustekinumab Biosimilar

Bio-Thera Solutions Partners with SteinCares to Market Two Biosimilars in LATAM

Celltrion’s Sub-cutaneous Zymfentra™ (infliximab-dyyb) US Launched

November 2023 PBAC Public Summary Documents Feature Biopharma

CuraTeQ’s Omalizumab Biosimilar (BP11) Phase I Completion

Biocon Enters Long-Term Commercial Collaboration with Eris Lifesciences in India

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Sign up to receive the latest life sciences industry news